Breaking News, Collaborations & Alliances

Chime Biologics, Hope Medicine Partner on Antibody Drug HMI-115

Hope Medicine will leverage Chime Biologics' extensive experience in 2000L cGMP manufacturing.

Chime Biologics, a contract development and manufacturing organization (CDMO), and Hope Medicine Inc., a clinical-stage biotech, are collaborating to develop and manufacture the first-in-class monoclonal antibody drug HMI-115. Under the terms of the agreement, Chime Biologics will provide a one-stop-shop CMC solution for Hope Medicine’s HMI-115 monoclonal antibody from technology transfer, process optimization, scale-up, clinical phase III GMP production, process characterization, proce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters